文献速递免疫规划

青少年接种四价A、C、W、Y群脑膜炎球菌结合疫苗后A、W、Y群免疫应答:最佳接种年龄

Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
PubMed 文献 · Vaccine · 2017-06-21

这项IV期开放标签研究评估10、12、15岁健康青少年接种四价MenACWY-TT疫苗后1个月和1年的MenA、MenW、MenY抗体水平,结果显示疫苗诱导稳健的保护性免疫应答,多数受试者1年后rSBA滴度≥128,12岁和15岁组MenW的rSBA GMT高于10岁组。

要点

  • MenACWY-TT疫苗在10、12、15岁青少年中诱导针对MenA、MenW、MenY的稳健免疫应答。
  • 接种1年后94%受试者对三个血清群rSBA滴度均≥128。
  • 12岁和15岁组接种1年后MenW rSBA GMT高于10岁组,MenA和MenY组间相似。

核心结论

  • MenACWY-TT疫苗诱导稳健的保护性初次免疫应答,持续至接种后1年。
  • 作者认为个体保护持久性随初次四价MenACWY-TT疫苗接种年龄增长而增加。
  • 作者认为12岁或15岁似乎是初次四价MenACWY-TT疫苗接种更优年龄,以应对MenW疾病的快速增长。

研究设计与样本

  • IV期开放标签研究,健康10岁、12岁和15岁青少年接种MenACWY-TT疫苗。
  • 接种前、接种后1个月和1年采集血样。
  • 采用幼兔补体血清杀菌试验(rSBA)检测MenA、MenW、MenY功能性抗体,采用荧光珠多重免疫分析检测MenA、MenW、MenY-PS特异性IgG、IgG1和IgG2。

主要发现

  • 四价MenACWY-TT疫苗诱导针对MenA、MenW和MenY的稳健抗体应答,多数(94%)受试者接种1年后对三个血清群rSBA滴度≥128。
  • 接种1年后,12岁和15岁组MenW rSBA GMT高于10岁组,而MenA和MenY的rSBA GMT在各年龄组间相似。
  • 基线rSBA滴度≥8的受试者接种1年后抗体水平高于基线rSBA滴度<8的受试者。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recently the incidence of meningococcal serogroup Y (MenY) and in particular serogroup W (MenW) invasive disease has risen in several European countries, including the Netherlands. Adolescents are a target group for primary prevention through vaccination to protect against disease and reduce carriage and induce herd protection in the population. The present study assessed MenA, MenW and MenY antibody levels in adolescents up to one year following primary vaccination with quadrivalent MenACWY-PS conjugated to tetanus toxoid (MenACWY-TT). METHODS: In this phase IV, open-label study, healthy 10-, 12- and 15-year-olds received the MenACWY-TT vaccine. Blood samples were collected before, 1month and 1year after the vaccination. Functional antibody levels against MenA, MenW and MenY were measured with serum bactericidal assay using baby rabbit complement (rSBA). MenA-, MenW-, and MenY-PS specific IgG, IgG1 and IgG2 levels were measured using fluorescent-bead-based multiplex immunoassay. RESULTS: The quadrivalent MenACWY-TT vaccine elicited robust antibody responses against MenA, MenW and MenY, and the majority (94%) of the participants maintained rSBA titers ≥128 one year after the vaccination against all three serogroups. After one year, higher MenW rSBA GMTs were observed in the 12- and 15-year-olds compared to the 10-year-olds, while rSBA GMTs against MenA and MenY were similar between age groups. Furthermore, those participant who showed SBA titer ≥8 at baseline, also had higher antibody levels one year after vaccination as compared to participants with rSBA titer <8 at baseline. CONCLUSION: The MenACWY-TT vaccine induces robust protective primary immune responses up to one year after vaccination. Our results suggest that persistence of individual protection increases with the age at which a primary quadrivalent MenACWY-TT vaccination is administered. Our results indicate that 12 or 15years seems a more optimal age for a primary quadrivalent MenACWY-TT vaccination to protect against the rapid increase of MenW disease.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. van Ravenhorst MB, van der Klis FRM, van Rooijen DM, et al. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination. Vaccine. 2017. PMID: 28647167. doi:10.1016/j.vaccine.2017.06.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。